CUE
Cue Biopharma, Inc.
$24.53
-9.45%
$103.0M
No data for this timeframe.
Vol
Market Cap$103.0M
Cap SizeMicro Cap
Insider Activity2B / 0S
Insider Net $$1000.0K
Reddit Sentiment72° Bullish
SEC Reports8
Press Releases4
Recent Activity
Jun 11, 2026
SEC
Sumita Ray filed a Form 3 initial statement of beneficial ownership after becoming Chief Legal Compliance Officer and Co
3 — Impact 2/10
Jun 5, 2026
SEC
Cue Biopharma filed an S-3 registration statement to register 4,090,908 shares of common stock for resale by selling sto
S-3 — Impact 6/10
Jun 2, 2026
SEC
Cue Biopharma announced the immediate resignation of four board members (Jill Broadfoot, Peter Kiener, Frank Morich, Pat
8-K — Impact 4/10
Jun 2, 2026
other
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
<p align="center"><em>Daniel Camardo, former CEO and executive commercial leader with a track record
Jun 1, 2026
Insider
Lin Shao-Lee bought 45,453 shares
Chief Executive Officer
Jun 1, 2026
Insider
Lin Shao-Lee bought 90,906 shares
Chief Executive Officer @ $11.00 ($1000.0K)
May 30, 2026
Insider
Camardo Daniel A. was granted 1,626 shares
Director
Apr 30, 2026
Press
Cue Biopharma licensed global rights (ex-China) to Ascendant-221, a Phase 2 anti-IgE antibody for allergic diseases, fro
Impact 6/10
Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$115.00 (Aug 2025)
Current $24.53
Low $115.00
Median $115.00
High $115.00
1 analysts
$115.00
$115.00
Analyst Ratings
1Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 25, 2025 | LUCID CAPITAL MARKETS | INITIATE | Buy |
| Apr 2, 2025 | Citizens Capital Markets | REITERATE | Market Outperform → Market Outperform |
| Aug 20, 2024 | Stifel | MAINTAIN | Buy → Buy |
| Jul 26, 2024 | JMP Securities | MAINTAIN | Market Outperform → Market Outperform |
| Jul 26, 2024 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.69 | $-1.69 — $-1.69 | 37% YoY | 1 |
| Next Q | $-1.91 | $-1.91 — $-1.91 | 9% YoY | 1 |
| Current FY | $-6.64 ▲ +61.8% | $-6.64 — $-6.64 | 21% YoY | 1 |
| Next FY | $-9.45 ▲ +47.5% | $-9.45 — $-9.45 | -42% YoY | 1 |
Latest Reports
NEUTRAL
3
2/10
Sumita Ray filed a Form 3 initial statement of beneficial ownership after becoming Chief Legal Compliance Officer and Co
Jun 11, 2026
BEARISH
S-3
6/10
Cue Biopharma filed an S-3 registration statement to register 4,090,908 shares of common stock for resale by selling sto
Jun 5, 2026
MIXED
Press
6/10
Cue Biopharma licensed global rights (ex-China) to Ascendant-221, a Phase 2 anti-IgE antibody for allergic diseases, fro
Apr 30, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Lin Shao-Lee | BUY | $0.00 |
| Jun 1, 2026 | Lin Shao-Lee | BUY | $1000.0K |
| May 30, 2026 | Camardo Daniel | A | $0.00 |
| May 30, 2026 | Meehan Viola | A | $0.00 |
| May 3, 2026 | Lin Shao-Lee | A | $0.00 |
Reddit Sentiment
72°▲
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
6 unique insiders with 9 transactions. Net insider value: $1000.0K ($1000.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Lin Shao-Lee | Chief Executive Officer | BUY | 45,453 | — | — |
| Jun 1, 2026 | Lin Shao-Lee | Chief Executive Officer | BUY | 90,906 | $11.00 | $1000.0K |
| May 30, 2026 | Camardo Daniel A. | Director | AWARD | 1,626 | — | — |
| May 30, 2026 | Meehan Viola Mong | Director | AWARD | 1,626 | — | — |
| May 3, 2026 | Lin Shao-Lee | CHIEF EXECUTIVE OFFICER | AWARD | 655,074 | — | — |
| May 3, 2026 | Lin Shao-Lee | CHIEF EXECUTIVE OFFICER | AWARD | 327,537 | — | — |
| Apr 9, 2026 | Sandercock Colin | SVP, GENERAL COUNSEL | AWARD | 200,000 | — | — |
| Apr 9, 2026 | Warren Lucinda | CHIEF BUSINESS OFFICER | AWARD | 250,000 | — | — |
| Apr 9, 2026 | Baker Daniel G. | CHIEF DEVELOPMENT OFFICER | AWARD | 100,000 | — | — |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 0 mixed, 4 neutral. Avg impact: 5.3/10.
NEUTRAL
3
2/10
Sumita Ray filed a Form 3 initial statement of beneficial ownership after becoming Chief Legal Compl
Jun 11, 2026
BEARISH
S-3
6/10
Cue Biopharma filed an S-3 registration statement to register 4,090,908 shares of common stock for r
Jun 5, 2026
NEUTRAL
8-K
4/10
Cue Biopharma announced the immediate resignation of four board members (Jill Broadfoot, Peter Kiene
Jun 2, 2026
NEUTRAL
8-K
5/10
Cue Biopharma implemented a 1-for-30 reverse stock split effective April 23, 2026, to comply with Na
Apr 22, 2026
BULLISH
8-K
7/10
Cue Biopharma announced it triggered a $7.5 million milestone payment from Boehringer Ingelheim afte
Apr 7, 2026
BEARISH
EFFECT
7/10
Cue Biopharma's S-3 shelf registration has become effective, allowing the company to raise up to $30
Apr 1, 2026
NEUTRAL
DEFA14A
4/10
Cue Biopharma's CEO and board member Usman Azam resigned, and Lucinda Warren was appointed interim C
Mar 27, 2026
BEARISH
S-3
7/10
Cue Biopharma (CUE) has filed an S-3 shelf registration, enabling it to raise up to $300 million thr
Mar 17, 2026
MIXED
6/10
Cue Biopharma licensed global rights (ex-China) to Ascendant-221, a Phase 2 anti-IgE antibody for al
Apr 30, 2026
BULLISH
6/10
Cue Biopharma announced it will receive a $7.5 million preclinical milestone payment from Boehringer
Apr 8, 2026
NEUTRAL
3/10
Cue Biopharma appointed Lucinda Warren as interim president and CEO following the departure of Usman
Mar 27, 2026
NEUTRAL
3/10
Cue Biopharma reported its fourth quarter and full year 2025 financial results. The press release an
Mar 16, 2026
Historical analyst distribution (last covering-analyst action Aug 2025): 80% buy across 5 analysts — 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$115.00 mean target (Aug 2025)
$115.00 Low
$115.00 High
| Metric | Value |
|---|---|
| Current Price | $24.53 |
| Target Low | $115.00 |
| Target Mean | $115.00 |
| Target Median | $115.00 |
| Target High | $115.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.69 | $-1.69 | $-1.69 | 37.4% | — | 0↑ 1↓ | $0.0B | 1.6% | 1 |
| Next Q 2026-09-30 |
$-1.91 | $-1.91 | $-1.91 | 9.1% | — | 1↑ 1↓ | $0.0B | -2.3% | 1 |
| Current FY 2026-12-31 |
$-6.64 | $-6.64 | $-6.64 | 21.0% | +61.8% | 0↑ 1↓ | $0.0B | -53.4% | 1 |
| Next FY 2027-12-31 |
$-9.45 | $-9.45 | $-9.45 | -42.3% | +47.5% | 0↑ 1↓ | $0.0B | -92.2% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.690 | |
| 7d ago | $0.000 | -1.690 |
| 30d ago | $0.000 | -1.690 |
| 60d ago | $0.000 | -1.690 |
| 90d ago | $0.000 | -1.690 |
11 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 9 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 25, 2025 | LUCID CAPITAL MARKETS | INITIATE | — | Buy |
| Apr 2, 2025 | Citizens Capital Markets | REITERATE | Market Outperform | Market Outperform |
| Aug 20, 2024 | Stifel | MAINTAIN | Buy | Buy |
| Jul 26, 2024 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Jul 26, 2024 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 9, 2024 | Stifel | MAINTAIN | Buy | Buy |
| Apr 9, 2024 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 3, 2024 | Piper Sandler | REITERATE | Overweight | Overweight |
| Mar 13, 2024 | Jefferies | INITIATE | — | Buy |
| Nov 6, 2023 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jun 15, 2023 | Stifel | REITERATE | Buy | Buy |
| May 15, 2023 | JMP Securities | REITERATE | Outperform | Outperform |
| Mar 22, 2023 | Stifel | MAINTAIN | — | Buy |
| Mar 22, 2023 | Oppenheimer | REITERATE | — | Outperform |
| Nov 21, 2022 | Piper Sandler | INITIATE | — | Overweight |
| Aug 24, 2022 | Oppenheimer | MAINTAIN | — | Outperform |
| Mar 21, 2022 | Oppenheimer | MAINTAIN | — | Outperform |
| Mar 18, 2022 | Craig-Hallum | MAINTAIN | — | Buy |
| Nov 24, 2020 | Berenberg | INITIATE | — | Buy |
| May 20, 2020 | Stifel | MAINTAIN | — | Buy |
| May 20, 2020 | Oppenheimer | MAINTAIN | — | Outperform |
| Apr 21, 2020 | Stifel | MAINTAIN | — | Buy |
| Apr 9, 2020 | Stifel | INITIATE | — | Buy |
| Mar 6, 2020 | JMP Securities | MAINTAIN | — | Outperform |
| Feb 25, 2020 | Oppenheimer | INITIATE | — | Outperform |
| Jan 28, 2020 | BTIG | INITIATE | — | Buy |
| Jan 22, 2020 | JMP Securities | INITIATE | — | Market Outperform |
| Jul 26, 2019 | Baird | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 2 | 3 | 1 | 0 | 0 | 83% | |
| Jan 1, 2026 | 2 | 3 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
72°
Bullish
Bearish
Neutral
Bullish
12 mentions
7 bullish
0 bearish
8 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 28, 2026 | 3 | 71° Bullish | 3 | 0 | 3 |
| May 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 2 | 53° Neutral | 0 | 0 | 2 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 22, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 22, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 16, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Jun 2, 2026
other
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
<p align="center"><em>Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board</em></p>
May 14, 2026
earnings
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering <pre>Moves de
May 7, 2026
other
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement
May 7, 2026
short_interest
FTD: CUE — 46,033 shares ($1.6M) failed to deliver
Settlement: 20260507, Price: $33.98, FTD Value: $1,564,201.34, CUE BIOPHARMA INC COM
May 6, 2026
short_interest
FTD: CUE — 40,979 shares ($1.4M) failed to deliver
Settlement: 20260506, Price: $34.94, FTD Value: $1,431,806.26, CUE BIOPHARMA INC COM
May 6, 2026
earnings_calendar
CUE Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
short_interest
FTD: CUE — 45,569 shares ($1.4M) failed to deliver
Settlement: 20260505, Price: $29.85, FTD Value: $1,360,234.65, CUE BIOPHARMA INC COM
May 4, 2026
short_interest
FTD: CUE — 79,632 shares ($2.4M) failed to deliver
Settlement: 20260504, Price: $30.42, FTD Value: $2,422,405.44, CUE BIOPHARMA INC COM
May 1, 2026
short_volume
Short Volume: CUE — 58.6% short (3.9M / 6.6M)
Short: 3,860,869 | Exempt: 18,664 | TRF Vol: 6,586,001 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_interest
FTD: CUE — 43,001 shares ($0.6M) failed to deliver
Settlement: 20260501, Price: $14.74, FTD Value: $633,834.74, CUE BIOPHARMA INC COM
Apr 30, 2026
offering
Cue Biopharma Announces $30 Million Private Placement
<p>BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class
Apr 30, 2026
fda
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
<p align="center"><em>Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases</em></
Apr 22, 2026
other
Cue Biopharma Announces 1-for-30 Reverse Stock Split
<p>BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kCTnPwFy8mitPnw6MbUuu2UWKRm1fOnJm4ZEoHzPS-LbVZz3Bm
Apr 20, 2026
short_volume
Short Volume: CUE — 57.1% short (8.0M / 14.0M)
Short: 7,968,245 | Exempt: 41,726 | TRF Vol: 13,951,272 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: CUE — 66.4% short (1.2M / 1.8M)
Short: 1,184,933 | Exempt: 240,231 | TRF Vol: 1,784,172 | Short Ratio: 66.4% | Off-exchange volume (dark pool + OTC)